SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

Section 1: Identification
Product name:

Ezetimibe / Simvastatin Formulation

Manufacturer or supplier's details
Company: Organon & Co.
Address:

30 Hudson Street, 33nd floor
Jersey City, New Jersey, U.S.A 07302

Telephone:+1-551-430-6000

Emergency telephone number :+1-215-631-6999

E-mail address

EHSSTEWARD@organon.com:

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical
Restrictions on use: Not applicable

Section 2: Hazard identification
GHS Classification
Skin corrosion/irritation:

Category 2

Skin sensitisation:

Category 1

Specific target organ toxicity repeated exposure:

Category 1 (Liver, muscle, optic nerve, Eye)

Hazardous to the aquatic
environment - chronic hazard:

Category 2

GHS label elements
Hazard pictograms:

Signal word:

DangerHazard statements:

H315 Causes skin irritation.
H317 May cause an allergic skin reaction.
H372 Causes damage to organs (Liver, muscle, optic nerve,Eye) through prolonged or repeated exposure.
H411 Toxic to aquatic life with long lasting effects.
1 / 21SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

Precautionary statements:

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

Prevention:
P261 Avoid breathing dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P272 Contaminated work clothing should not be allowed out of
the workplace.
P273 Avoid release to the environment.
P280 Wear protective gloves.
Response:
P302 + P352 IF ON SKIN: Wash with plenty of water.
P314 Get medical advice/ attention if you feel unwell.
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.
P362 + P364 Take off contaminated clothing and wash it before
reuse.
P391 Collect spillage.
Disposal:
P501 Dispose of contents/ container to an approved waste
disposal plant.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
May form explosive dust-air mixture during processing, handling or other means.
Section 3: Composition/information on ingredients
Substance / Mixture:

MixtureComponents
Chemical name
Cellulose
Ezetimibe
Simvastatin
Magnesium stearate

CAS-No.
9004-34-6
163222-33-1
79902-63-9
557-04-0

Concentration (% w/w)>= 10 -< 20>= 10 -< 20>= 10 -< 20>= 1 -< 10Section 4: First-aid measures
General advice:

In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical
advice.

If inhaled:

In case of skin contact:

If inhaled, remove to fresh air.
Get medical attention if symptoms occur.
In case of contact, immediately flush skin with plenty of water
for at least 15 minutes while removing contaminated clothing
and shoes.
Get medical attention.
2 / 21SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

In case of eye contact:

If swallowed:

Most important symptoms
and effects, both acute anddelayed:Protection of first-aiders:

Notes to physician:

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

Wash clothing before reuse.
Thoroughly clean shoes before reuse.
If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.
Causes skin irritation.
May cause an allergic skin reaction.
Causes damage to organs through prolonged or repeatedexposure.
Dust contact with the eyes can lead to mechanical irritation.
First Aid responders should pay attention to self-protection,and use the recommended personal protective equipment
when the potential for exposure exists (see section 8).
Treat symptomatically and supportively.

Section 5: Fire-fighting measures
Suitable extinguishing media:

Unsuitable extinguishingmedia
Specific hazards during firefighting::

Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical
None known.
Avoid generating dust; fine dust dispersed in air in sufficientconcentrations, and in the presence of an ignition source is apotential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- :ucts

Carbon oxides
Nitrogen oxides (NOx)
Fluorine compounds
Metal oxides

Specific extinguishing methods:

Special protective equipment
for firefighters
Hazchem Code:Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to doso.
Evacuate area.
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.
2Z:

Section 6: Accidental release measures
Personal precautions, protec- :tive equipment and emergency procedures

Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions

Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.

:

3 / 21SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages
cannot be contained.
Methods and materials forcontainment and cleaning up:

Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces
with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items
employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding
certain local or national requirements.

Technical measures:

Local/Total ventilation
Advice on safe handling::

Hygiene measures:

Static electricity may accumulate and ignite suspended dust
causing an explosion.
Provide adequate precautions, such as electrical grounding
and bonding, or inert atmospheres.
Use only with adequate ventilation.
Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety
practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to theenvironment.
If exposure to chemical is likely during typical use, provide eye
flushing systems and safety showers close to the working
place.
When using do not eat, drink or smoke.
Contaminated work clothing should not be allowed out of theworkplace.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review ofengineering controls, proper personal protective equipment,
appropriate degowning and decontamination procedures,industrial hygiene monitoring, medical surveillance and theuse of administrative controls.

Section 7: Handling and storage

4 / 21SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

Conditions for safe storage:

Materials to avoid:

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

Keep in properly labelled containers.
Store in accordance with the particular national regulations.
Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection
Components with workplace control parameters
Components

CAS-No.

Value type
(Form ofexposure)
9004-34-6
WES-TWA
TWA
163222-33-1 TWA
Wipe limit
79902-63-9
TWA
Further information: DSEN
Wipe limit
557-04-0
WES-TWATWA (Inhalable particulate matter)
TWA (Respirable particulate matter)

Cellulose
Ezetimibe
Simvastatin

Magnesium stearate

Engineering measures:

Control parameters / Permissible
concentration
10 mg/m3
10 mg/m3
25 µg/m3 (OEB 3)
250 µg/100 cm²
25 µg/m3 (OEB 3)

Basis

250 µg/100 cm²
10 mg/m3
10 mg/m3

InternalNZ OEL
ACGIH

3 mg/m3

ACGIH

NZ OELACGIHInternal
Internal
Internal

All engineering controls should be implemented by facility
design and operated in accordance with GMP principles toprotect products, workers, and the environment.
Containment technologies suitable for controlling compounds
are required to control at source and to prevent migration of
the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment
Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type
: Particulates type
Hand protection

Material:

Chemical-resistant gloves

Remarks
Eye protection::

Consider double gloving.
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions,
5 / 21SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

Skin and body protection

SDS Number:
28133-00022

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is apotential for direct contact to the face with dusts, mists, oraerosols.
Work uniform or laboratory coat.
Additional body garments should be used based upon thetask being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentiallycontaminated clothing.

:

Section 9: Physical and chemical properties
Appearance:

powderColour:No data available

Odour

:

No data available

Odour Threshold:

No data available

pH:

No data available

Melting point/freezing point:

No data available

Initial boiling point and boiling
range

:

No data available

Flash point:

No data available

Evaporation rate:

No data available

Flammability (solid, gas):

May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids):

No data available

Upper explosion limit / Upper
flammability limit:

No data available

Lower explosion limit / Lower
flammability limit:

No data available

Vapour pressure:

No data available

Relative vapour density:

No data available

Relative density:

No data available

Solubility(ies)
Water solubility:

No data available

Partition coefficient: n-:

No data available
6 / 21SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

octanol/water
Auto-ignition temperature:

No data available

Decomposition temperature:

No data available

Viscosity
Viscosity, kinematic:

No data available

Explosive properties:

Not explosive

Oxidizing properties:

The substance or mixture is not classified as oxidizing.

Molecular weight:

No data available

Particle size:

No data available

Reactivity
Chemical stability
Possibility of hazardous reactions:::

Not classified as a reactivity hazard.
Stable under normal conditions.
May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid:

Incompatible materials
Hazardous decomposition
products::

Heat, flames and sparks.
Avoid dust formation.
Oxidizing agents
No hazardous decomposition products are known.

Section 10: Stability and reactivity

Section 11: Toxicological information
Exposure routes:

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.
Components:
Cellulose:
Acute oral toxicity:

LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity:

LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity:

LD50 (Rabbit): > 2,000 mg/kg
7 / 21SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

Ezetimibe:
Acute oral toxicity

SDS Number:
28133-00022:

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): > 5,000 mg/kg
LD50 (Dog): > 3,000 mg/kg

Acute inhalation toxicity:

Remarks: No data available

Acute dermal toxicity:

Remarks: No data available

Acute toxicity (other routes of :administration)

LD50 (Rat): > 2,000 mg/kg
Application Route: Intraperitoneal
LD50 (Mouse): > 1,000 - < 2,000 mg/kg
Application Route: Intraperitoneal

Simvastatin:
Acute oral toxicity:

LD50 (Rat): 5,000 mg/kg
LD50 (Mouse): 3,800 mg/kg

Magnesium stearate:
Acute oral toxicity:

LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity:

LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Ezetimibe:
SpeciesResult::RabbitNo skin irritation

Simvastatin:
Species
Remarks::

RabbitModerate skin irritation

Magnesium stearate:
Species:

RabbitSkin corrosion/irritation
Causes skin irritation.
Components:

8 / 21SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

ResultRemarks

SDS Number:
28133-00022::

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

No skin irritation
Based on data from similar materials

Serious eye damage/eye irritation
Not classified based on available information.
Components:
Ezetimibe:
SpeciesResult::RabbitNo eye irritation

Simvastatin:
Species
Remarks::

Rabbitslight irritation

Magnesium stearate:
SpeciesResultRemarks:::

RabbitNo eye irritation
Based on data from similar materials

Respiratory or skin sensitisation
Skin sensitisation
May cause an allergic skin reaction.
Respiratory sensitisation
Not classified based on available information.
Components:
Ezetimibe:
Test TypeSpeciesResult:::Maximisation Test
Guinea pig
negative

Simvastatin:
Assessment
Result::Probability or evidence of skin sensitisation in humans
positive

Magnesium stearate:
Test Type
Exposure routes
Species
MethodResultRemarks

:
:
:
:
:
:

Maximisation Test
Skin contact
Guinea pig
OECD Test Guideline 406
negative
Based on data from similar materials

9 / 21SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

Chronic toxicity
Germ cell mutagenicity
Not classified based on available information.
Components:
Cellulose:
Genotoxicity in vitro:

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo:

Test Type: Mammalian erythrocyte micronucleus test (in vivo
cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Ezetimibe:
Genotoxicity in vitro:

Test Type: Bacterial reverse mutation assay (AMES)
Metabolic activation: with and without metabolic activation
Result: negative
Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: negative

Genotoxicity in vivo:

Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Simvastatin:
Genotoxicity in vitro:

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: Alkaline elution assay
Result: negative
Test Type: Chromosomal aberration
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo:

Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
10 / 21

SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

Result: negative
Germ cell mutagenicity Assessment
Magnesium stearate:
Genotoxicity in vitro:

Weight of evidence does not support classification as a germ
cell mutagen.

:

Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials
Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity
Not classified based on available information.
Components:
Cellulose:
Species
Application RouteExposure time
Result

:
:
:
:

Rat
Ingestion
72 weeks
negative

Ezetimibe:
Species
Application RouteExposure time
Result::::Rat, female
oral (feed)
104 weeks
negative

Species
Application RouteExposure time
Result::::Rat, maleoral (feed)
104 weeks
negative

Species
Application RouteExposure time
Result

:
:
:
:

Mouse
oral (feed)
104 weeks
negative

Simvastatin:
Species
Application RouteExposure time

:
:
:

Mouse
Oral
< 92 weeks
11 / 21

SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

Target Organs
Tumor Type
Remarks:::

Harderian gland
Liver, Lungs
The significance of these findings for humans is not certain.

Species
Application RouteExposure time
Tumor Type
Remarks

:
:
:
:
:

Rat
Oral
2 Years
Liver, Thyroid
The significance of these findings for humans is not certain.

Reproductive toxicity
Not classified based on available information.
Components:
Cellulose:
Effects on fertility

Effects on foetal development

Ezetimibe:
Effects on fertility

Effects on foetal development:

Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative:

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative:

Test Type: Fertility/early embryonic development
Species: Rat, male and female
Fertility: NOAEL: > 1,000 mg/kg body weight
Result: No effects on fertility, No fetotoxicity:

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight
Result: No adverse effects
Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight
Result: No adverse effects

Simvastatin:
Effects on fertility:

Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: LOAEL: 25 mg/kg body weight

Effects on foetal develop-:

Test Type: Embryo-foetal development
12 / 21

SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

ment

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

Species: Rat
Application Route: Oral
Embryo-foetal toxicity: NOAEL: 25 mg/kg body weight
Result: No teratogenic effects, No adverse effects
Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Embryo-foetal toxicity: NOAEL: 10 mg/kg body weight
Result: No teratogenic effects, No adverse effects
Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Embryo-foetal toxicity: LOAEL: 60 mg/kg body weight
Result: Teratogenic potential
Remarks: Based on data from similar materials

Magnesium stearate:
Effects on fertility

Effects on foetal development:

Test Type: Combined repeated dose toxicity study with thereproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials:

Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure
Not classified based on available information.
STOT - repeated exposure
Causes damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.
Components:
Simvastatin:
Target Organs
Assessment::

Liver, muscle, optic nerve, Eye
Causes damage to organs through prolonged or repeatedexposure.

13 / 21

SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

Repeated dose toxicity
Components:
Cellulose:
Species
NOAEL
Application RouteExposure time

:
:
:
:

Rat
>= 9,000 mg/kg
Ingestion
90 DaysEzetimibe:
Species
NOAEL
Application RouteExposure time
Remarks

:
:
:
:
:

Dog
1,000 mg/kg
Oral
90 d
No significant adverse effects were reported

Species
NOAEL
Application RouteExposure time
Remarks

:
:
:
:
:

Rat
1,500 mg/kg
Oral
90 d
No significant adverse effects were reported

Species
NOAEL
Application RouteExposure time
Remarks

:
:
:
:
:

Mouse
500 mg/kg
Oral
90 d
No significant adverse effects were reported

Species
NOAEL
Application RouteExposure time
Remarks

:
:
:
:
:

Dog
300 mg/kg
Oral
1 yr
No significant adverse effects were reported

Simvastatin:
Species
NOAEL
LOAEL
Application RouteExposure timeTarget Organs

:
:
:
:
:
:

Rat
5 mg/kg
30 mg/kg
Oral
14 - 104 Weeks
Liver, Testis, Musculo-skeletal system, Eye

Species
LOAEL
Application RouteExposure timeTarget Organs

:
:
:
:
:

Dog
10 mg/kg
Oral
14 - 104 Weeks
Liver, Testis, Eye

Species
NOAEL::

Rabbit30 mg/kg
14 / 21

SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

LOAEL
Application Route
Target Organs:::

50 mg/kg
Oral
Liver, Kidney

Magnesium stearate:
Species
NOAEL
Application RouteExposure time
Remarks

:
:
:
:
:

Rat
> 100 mg/kg
Ingestion
90 DaysBased on data from similar materials

Aspiration toxicity
Not classified based on available information.
Components:
Ezetimibe:
Not applicable
Experience with human exposure
Components:
Ezetimibe:Ingestion:

Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatulence, muscle pain, upper respiratory tract infection, Backpain, joint pain

Simvastatin:
Skin contact
Ingestion::

Remarks: May produce an allergic reaction.
Target Organs: Liver
Symptoms: upper respiratory tract infection, Headache, Abdominal pain, constipation, Nausea
Target Organs: Musculo-skeletal system

Section 12: Ecological information
Ecotoxicity
Components:
Cellulose:
Toxicity to fish:

LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Ezetimibe:
Toxicity to fish:

LC50 (Pimephales promelas (fathead minnow)): > 0.125 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
15 / 21

SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and otheraquatic invertebrates:

EC50 (Daphnia magna (Water flea)): > 4 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquaticplants:

EC50 (Pseudokirchneriella subcapitata (green algae)): >0.317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility
NOEC (Pseudokirchneriella subcapitata (green algae)): 0.317
mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity):

NOEC (Pimephales promelas (fathead minnow)): 0.051 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210
NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l
Exposure time: 7 dRemarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :aquatic invertebrates (Chronic toxicity)

NOEC (Daphnia magna (Water flea)): 0.282 mg/l
Exposure time: 21 d
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic
toxicity)
Toxicity to microorganisms

:

1

:

EC50: > 4.4 mg/l
Exposure time: 3 hTest Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility
NOEC: 4.4 mg/l
Exposure time: 3 hTest Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

Simvastatin:
Toxicity to fish

Toxicity to daphnia and otheraquatic invertebrates:

LC50 (Pimephales promelas (fathead minnow)): 2.91 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203:

EC50 (Daphnia magna (Water flea)): 3.5 mg/l
Exposure time: 48 h
16 / 21

SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

Method: OECD Test Guideline 202
Toxicity to algae/aquaticplants:

EC50 (Pseudokirchneriella subcapitata (green algae)): > 25
mg/l
Exposure time: 96 h
NOEC (Pseudokirchneriella subcapitata (green algae)): 25
mg/l
Exposure time: 96 h

Toxicity to microorganisms:

EC50: > 30 mg/l
Exposure time: 3 hTest Type: Respiration inhibition
Method: OECD Test Guideline 209
NOEC: 21 mg/l
Exposure time: 3 hTest Type: Respiration inhibition
Method: OECD Test Guideline 209

Magnesium stearate:
Toxicity to fish:

LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and otheraquatic invertebrates:

EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

Toxicity to algae/aquaticplants:EL50 (Pseudokirchneriella subcapitata (green algae)): > 1
mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility
NOELR (Pseudokirchneriella subcapitata (green algae)): > 1
mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms:

EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials
17 / 21

SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

Persistence and degradability
Components:
Cellulose:
Biodegradability:

Result: Readily biodegradable.

Ezetimibe:
Biodegradability:

Result: Not readily biodegradable.
Biodegradation: 6.8 %Exposure time: 28 d

Stability in water:

Hydrolysis: 50 %(4.5 d)
Method: OECD Test Guideline 111

Simvastatin:
Biodegradability:

Result: rapidly degradable

Stability in water:

Hydrolysis: 50 %(3.2 d)Magnesium stearate:
Biodegradability:

Result: Not biodegradable
Remarks: Based on data from similar materials:

Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 173
Exposure time: 97 d
Method: OECD Test Guideline 305:

log Pow: 4.36

Simvastatin:
Partition coefficient: noctanol/water:log Pow: > 4.07

Magnesium stearate:
Partition coefficient: noctanol/water:log Pow: > 4

Bioaccumulative potential
Components:
Ezetimibe:
Bioaccumulation

Partition coefficient: noctanol/water

Mobility in soil
Components:
Ezetimibe:
18 / 21

SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

Distribution among environmental compartments

SDS Number:
28133-00022:

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

log Koc: 4.35
Method: OECD Test Guideline 106

Other adverse effects
No data available
Section 13: Disposal considerations
Disposal methods
Waste from residues:

Contaminated packaging:

Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information
International Regulations
UNRTDGUN number
Proper shipping name

:
:

Class
Packing group
LabelsEnvironmentally hazardous

:
:
:
:

IATA-DGR
UN/ID No.
Proper shipping name::UN 3077
ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,
N.O.S.
(Ezetimibe, Simvastatin)
9
III
9
yes

:
:
:
:

UN 3077
Environmentally hazardous substance, solid, n.o.s.
(Ezetimibe, Simvastatin)
9
III
Miscellaneous
956

:

956

:

yes

IMDG-CodeUN number
Proper shipping name

:
:

Class
Packing group
LabelsEmS Code
Marine pollutant

:
:
:
:
:

UN 3077
ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,
N.O.S.
(Ezetimibe, Simvastatin)
9III
9F-A, S-F
yes

Class
Packing group
LabelsPacking instruction (cargo
aircraft)Packing instruction (passenger aircraft)
Environmentally hazardous

19 / 21

SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

SDS Number:
28133-00022

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC CodeNot applicable for product as supplied.
National Regulations
NZS 5433
UN number
Proper shipping name

:
:

Class
Packing group
LabelsHazchem CodeMarine pollutant

:
:
:
:
:

UN 3077
ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,
N.O.S.
(Ezetimibe, Simvastatin)
9
III
9
2Z
no

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely
based upon the properties of the unpackaged material as it is described within this Safety Data
Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.
Section 15: Regulatory information
Safety, health and environmental regulations/legislation specific for the substance or mixture
HSNO Approval Number
HSR100425 Pharmaceutical Active Ingredients Group Standard
HSW Controls
Certified handler certificate not required.
Tracking hazardous substance not required.
Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.
The components of this product are reported in the following inventories:
AICS: not determinedDSL:

not determined

IECSC

:

not determined

Revision Date:

30.09.2023

Further information
Sources of key data used tocompile the Safety Data
Sheet

:

Internal technical data, data from raw material SDSs, OECD
eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Section 16: Other information

20 / 21

SAFETY DATA SHEET

Ezetimibe / Simvastatin Formulation
Version
8.1

Revision Date:
30.09.2023

Date format

SDS Number:
28133-00022:

Date of last issue: 04.04.2023
Date of first issue: 04.11.2014

dd.mm.yyyy

Full text of other abbreviations
ACGIH: USA. ACGIH Threshold Limit Values (TLV)NZ OEL: New Zealand. Workplace Exposure Standards for Atmospheric Contaminants
ACGIH / TWANZ OEL / WES-TWA::

8-hour, time-weighted average
Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport byLand of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute forStandardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with
x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule;
ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with
x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA
- International Air Transport Association; IBC - International Code for the Construction andEquipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International
Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median
Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships;
n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) EffectConcentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable EffectLoading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New
Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No
1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance forsafe handling, use, processing, storage, transportation, disposal and release and shall not be
considered a warranty or quality specification of any type. The information provided relates only
to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text.
Material users should review the information and recommendations in the specific context of theirintended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.
NZ / EN
21 / 21